These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 15579793)

  • 1. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility.
    Balen AH; Mulders AG; Fauser BC; Schoot BC; Renier MA; Devroey P; Struijs MJ; Mannaerts BM
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6297-304. PubMed ID: 15579793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
    Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
    Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study.
    Hugues JN; Soussis J; Calderon I; Balasch J; Anderson RA; Romeu A;
    Hum Reprod; 2005 Mar; 20(3):629-35. PubMed ID: 15618252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study.
    Hugues JN; Cédrin-Durnerin I; Howles CM; ; Amram M; Angelini A; Balen A; Barbereau D; Birkhauser M; Boujenah A; De Leo V; De Placido G; Dessole S; Favrin S; Ferrazi E; Gay C; Germond M; Hedon B; Hocke C; Jolly C; Lamarca-Roth E; Lanzone A; Marchand F; Marcolin G; Mascaretti G; Moreau L; Massobrio M; Nappi C; Pardi G; Pennehouat G; Porcu E; Seibert M; Selvaggi L; Thiers D; Venturini P
    Hum Reprod; 2006 Nov; 21(11):2817-22. PubMed ID: 16877376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females.
    Duijkers IJ; Klipping C; Boerrigter PJ; Machielsen CS; De Bie JJ; Voortman G
    Hum Reprod; 2002 Aug; 17(8):1987-93. PubMed ID: 12151425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group.
    J Clin Endocrinol Metab; 1998 May; 83(5):1507-14. PubMed ID: 9589647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follicular characteristics and luteal development after follicle-stimulating hormone induced multiple ovulations in heifers.
    Glick G; Hogeg M; Moallem U; Lavon Y; Wolfenson D
    J Anim Sci; 2013 Jan; 91(1):188-94. PubMed ID: 23097398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development.
    Schipper I; Hop WC; Fauser BC
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1292-8. PubMed ID: 9543158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens.
    van Santbrink EJ; Fauser BC
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3597-602. PubMed ID: 9360513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between inhibin A and B, estradiol and follicle growth dynamics during ovarian stimulation in normo-ovulatory women.
    Hohmann FP; Laven JS; de Jong FH; Fauser BC
    Eur J Endocrinol; 2005 Mar; 152(3):395-401. PubMed ID: 15757856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with recombinant equine follicle stimulating hormone (reFSH) followed by recombinant equine luteinizing hormone (reLH) increases embryo recovery in superovulated mares.
    Meyers-Brown G; Bidstrup LA; Famula TR; Colgin M; Roser JF
    Anim Reprod Sci; 2011 Oct; 128(1-4):52-9. PubMed ID: 22005252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome.
    Lie Fong S; Schipper I; de Jong FH; Themmen AP; Visser JA; Laven JS
    Fertil Steril; 2011 Aug; 96(2):459-63. PubMed ID: 21719005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
    Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS
    J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction.
    Serour GI; Aboulghar M; Al Bahar A; Hugues JN; Esmat K
    Reprod Biol Endocrinol; 2014 Jun; 12():52. PubMed ID: 24942155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of estradiol and inhibin to the follicle-stimulating hormone variability in hypergonadotropic hypogonadism or premature ovarian failure.
    Welt CK; Hall JE; Adams JM; Taylor AE
    J Clin Endocrinol Metab; 2005 Feb; 90(2):826-30. PubMed ID: 15562017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.
    Fauser BC; Mannaerts BM; Devroey P; Leader A; Boime I; Baird DT
    Hum Reprod Update; 2009; 15(3):309-21. PubMed ID: 19182099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corifollitropin alfa, a long-acting follicle-stimulating hormone agonist for the treatment of infertility.
    Loutradis D; Drakakis P; Vlismas A; Antsaklis A
    Curr Opin Investig Drugs; 2009 Apr; 10(4):372-80. PubMed ID: 19337959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.